The training requirements for the supervision and administration of therapeutic procedures using radiopharmaceuticals are not defined uniformly in the Accreditation Council of Graduate Medical Education (ACGME) program requirements for different specialties. The training requirements of the Nuclear Regulatory Commission (NRC) are intended for the safe handling of radioisotopes, which is only a prerequisite to the safe practice of medicine.
The purpose of this document is to recommend the minimum training requirements for therapeutic procedures using radiopharmaceuticals. These requirements should be uniform across ACGME specialty training requirements. This training must include independently evaluating and treating, under supervision, a minimum of 10 cases of radioiodine therapy for hyperthyroidism, a minimum of 5 cases of radioiodine therapy for thyroid carcinoma, and a minimum of 3 cases of parenteral radionuclide therapy. Less training and experience is inadequate to ensure the safety, appropriateness, and effectiveness of radionuclide therapy.
I. GENERAL

A. The Joint Commission (formerly known as the Joint
Commission for the Accreditation of Hospitals) requires that a system be in place for delineating privileges for every hospital staff member. The Joint Commission does not, however, spell out specific qualifications for any given privilege or level of privilege. Privileges are generally hospital-specific and are not usually transferable from hospital to hospital. B. The granting of clinical privileges cannot and should not depend on only a single criterion, such as board certification or membership in a particular specialty society. Other criteria should also be used, such as documented evidence of training, experience, and judgment and demonstrated current competence. C. It is the final responsibility of the hospital medical staff and hospital governing board to ensure that a physician meets a reasonable standard of competency. D. The SNM, American College of Nuclear Medicine (ACNM), and American Board of Nuclear Medicine (ABNM) have reviewed the current ACGME training requirements for nuclear medicine, radiology, nuclear radiology, and radiation oncology and the guidelines from other specialty societies and endorse the recommendations given in section II.D below.
II. SUMMARY OF CURRENT REQUIREMENTS FOR THERAPEUTIC PROCEDURES USING RADIOPHARMACEUTICALS
A. Certification requirements for physicians supervising and administering therapeutic procedures using radiopharmaceuticals: Physicians supervising and administering therapeutic procedures using radiopharmaceuticals must be certified by one of the following specialty boards of the American Board of Medical Specialties, which include training for therapeutic procedures using radiopharmaceuticals: . .will obtain patient information relevant to the requested test or therapy using patient interview, chart and computer data base review, physical examination, and contact with referring physician;" e. Section IV.A.5.a).(2) Residents "will select appropriate procedures or therapy based on the referring physician's request and the patient's history." f. Section IV.A.5.a).(4) Residents "will conduct therapeutic procedures. Therapeutic procedures must be done in consultation with an attending physician who is a licensed user of radioactive material. These procedures should include dose calculation, patient identity verification, explanation of informed consent, documentation of pregnancy status, counseling of patients and their families on radiation safety issues, and scheduling follow-up after therapy." g. Section IV.A.5.a). perience with "therapeutic administration of radiopharmaceuticals, to include patient selection and understanding and calculation of the administered dose. Specific applications should include radioiodine in hyperthyroidism (minimum of 10 cases) and thyroid carcinoma (minimum of five cases), radiolabeled antibodies (minimum of three cases). . . ." Parenteral radionuclide therapy currently includes radiolabeled antibodies for the treatment of lymphoma, radionuclide for the treatment of bone metastasis and radiolabeled microspheres for the treatment of liver metastasis. "Program directors must be able to document the experience of residents in this area, including patient follow-up, (e.g., with logbooks);" k. Section IV.A.5.b).(1) Residents "will closely follow scientific progress in nuclear medicine, and learn to incorporate it effectively for modifying and improving diagnostic and therapeutic procedures;" l. Sections IV.A.5.b). (7), IV.A.5.b). (9) (3) The residents "must participate in the administration of no fewer than six procedures using radioimmunotherapy, other targeted therapeutic radiopharmaceuticals, or unsealed radioactive sources;" b. Section IV.A.5.a). (7) (iv). "There must be at least 80 hours of didactic (classroom and laboratory training) training under the direction of an authorized user (AU). This training must include the following subjects as they relate to nuclear medicine:. . .safe handling and administration of therapeutic doses of unsealed radionuclide sources (i.e., I-131 D. The SNM, ACNM, and ABNM believe that the minimum training requirements of the NRC for the handling and use of radiopharmaceuticals are intended for the radiation safety of patients, health care workers, and the public. The medical treatment of patients with therapeutic radiopharmaceuticals for benign and malignant diseases involves considerably more than just radiation safety. It requires extensive training and experience that should include the following:
1. Review of the request form and patient medical record 2. Review of relevant laboratory values, including pregnancy testing, if appropriate 3. Review of imaging studies as appropriate 4. Interview of the patient to obtain history 5. Examination of the patient as appropriate 6. Full explanation of the procedure, answering all patient questions (including risks and radiation safety precautions) and obtaining informed consent 7. Calculation of the dose to be administered 8. Supervision of administration of the dose to the patient 9. Arrangement for appropriate follow-up
The SNM, ACNM, and ABNM believe that the ACGME nuclear medicine program requirements are minimum requirements for safe supervision and effective administration of therapeutic procedures using radiopharmaceuticals, especially for patients who are being treated for cancer. Training and experience that do not fulfill ACGME nuclear medicine program requirements are inadequate to ensure the safety and effectiveness of radionuclide therapy. The minimum requirements for supervision and administration of therapeutic procedures using radiopharmaceuticals (defined in the ACGME Nuclear Medicine Program Requirements) include independently evaluating and treating, under supervision, a minimum of 10 cases of radioiodine therapy for hyperthyroidism, a minimum of 5 cases of radioiodine therapy for thyroid carcinoma, and a minimum of 3 cases of parenteral radionuclide therapy. Additional experience can be gained after residency training under the supervision of a qualified physician if experience during residency training does not meet these recommendations. Such supplementation will count toward fulfilling the minimum numbers of case experiences recommended in this statement.
E. Physicians need to participate in maintenance of certification as required by the specialty board. There needs to be evidence of continuing competence in the safe supervision and effective administration of therapeutic procedures using radiopharmaceuticals.
